Table 6 Comparison of the demographics between patients with AOSD with or without DRB1*15:01 or DR5
DRB1*15:01 (+) | DRB1*15:01 (-) | P | DR5 (+) | DR5 (-) | P | |
|---|---|---|---|---|---|---|
Number | 29 | 58 | 23 | 64 | ||
Female, n (%) | 24 (82.7) | 45 (77.5) | 0.7789 | 20 (86.9) | 49 (77.4) | 0.2912 |
Age at onset (years) | 46.6 ± 20.3 | 50.6 ± 19.6 | 0.3980 | 50.6 ± 20.5 | 48.1 ± 19.7 | 0.7469 |
Ferritin (ng/mL) | 12818.5 ± 18292.9 | 10555.5 ± 16284.7 | 0.3657 | 12669.4 ± 16305.9 | 10802.9 ± 17224.9 | 0.3243 |
CRP (mg/dL) | 11.9 ± 8.2 | 12.7 ± 8.3 | 0.6802 | 12.0 ± 9.2 | 12.6 ± 7.9 | 0.5068 |
ESR (mm(1 h)) | 59.6 ± 25.3 | 75.4 ± 30.9 | 0.1289 | 67.4 ± 23.0 | 72.5 ± 32.5 | 0.9361 |
Liver dysfunction, n (%) | 24 (82.7) | 44 (75.8) | 0.4630 | 19 (82.6) | 49 (76.5) | 0.5472 |
MAS, n (%) | 10 (38.6) | 13 (22.4) | 0.2288 | 10 (43.4) | 13 (20.3) | 0.0307 |
Initial dose of PSL (mg/day) | 43.8 ± 13.0 | 41.5 ± 11.7 | 0.4379 | 46.1 ± 10.9 | 40.3 ± 12.4 | 0.1184 |
Steroid pulse, n (%) | 17 (58.6) | 38 (65.5) | 0.4987 | 19 (82.6) | 36 (56.2) | 0.0245 |
Immunosuppressant, n (%) | 18 (57.6) | 33 (56.8) | 0.6442 | 15 (65.2) | 36 (56.2) | 0.4539 |
Biologics, n (%) | 10 (38.6) | 16 (27.5) | 0.5077 | 6 (26.0) | 20 (31.2) | 0.6427 |
Polycyclic systemic type, n (%) | 20 (68.9) | 36 (62.0) | 0.5266 | 18 (78.2) | 38 (59.3) | 0.1048 |
Monocyclic systemic type, n (%) | 8 (27.5) | 13 (22.4) | 0.5951 | 4 (17.3) | 17 (26.5) | 0.3780 |
Chronic arthritis type, n (%) | 4 (13.7) | 8 (13.7) | 1.0000 | 2 (8.6) | 10 (15.6) | 0.4085 |
Relapse, n (%) | 14 (48.2) | 26 (44.8) | 0.7619 | 11 (47.8) | 29 (45.3) | 0.8357 |